Ranbaxy Laboratories jumped 9.08 per cent to close at Rs 279.25 on Wednesday on reports that the US Department of Justice has withdrawn a legal motion against the company, which charged it of fraudulent practices.
According to the instructions, Ranbaxy has provided the US department a comprehensive set of audit documents, which will help resolve the questions raised by the US government about the company’s business practices and standards. The stock hit an intraday high of Rs 284 and a new 52-week low of Rs 236.
